Lates News

According to Every Investment AI, Huayuan Securities released a research report on November 4th, giving Buy rating to Baiyang Medicine (301015.SZ). The rating reasons mainly include: 1) the steady growth of brand operation business and continuous contraction of wholesale distribution business; 2) continuous improvement of gross profit margin and continuous increase in market promotion expenses. (Daily Economic News)